syngene International Limited (NSEI:SYNGENE) entered into a binding term sheet to acquire Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 7 billion on July 4, 2023. syngene International Limited (NSEI:SYNGENE) agreed to acquire Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 7 billion on September 30, 2023. The transaction has been approved independently by the respective Boards of Directors of Syngene International Limited and Stelis Biopharma Private Limited. Transaction is subject to including receiving the required lender and regulatory approvals. The transaction is expected to close within 90 days.

syngene International Limited (NSEI:SYNGENE) completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion on December 1, 2023.